Antimetabolites.pdf

Antineoplastic agents, Anticancer agents, antimetabolites reference slides for T Y B Pharm, Sem V (PCI).

1. Antimetabolites
(Antineplastic Agents)
by
Prof. Jayshree Patil
Assistant Professor
AIKTC, School of Pharmacy, New Panvel
For T Y B Pharm (Sem V, PCI)

2. ➢Mercaptopurine*,
➢Thioguanine,
➢Fluorouracil,
➢Floxuridine,
➢Cytarabine,
➢Methotrexate*,
➢Azathioprine

3. Antimetabolites are compounds closely related in structure to a cellular precursor
molecule.
Most antimetabolites are effective cancer chemotherapeutic agents via interaction
with the biosynthesis of nucleic acids. Therefore, several of the useful drugs used
in antimetabolite therapy are purines, pyrimidines, folates, and related compounds.
The antimetabolite drugs may exert their effects by several individual mechanisms
involving enzyme inhibition at active, allosteric, or related sites. Most of these
targeted enzymes and processes are involved in the regulatory steps of cell
division and cell/tissue growth.
Often the administered drug is actually a prodrug form of an antimetabolite and
requires activation in vivo to yield the active inhibitor
These substances are generally cell cycle specific with activity in the S phase.

5. Purine Antagonists: Amidophosphoribosyl Transferase Inhibitors
The rate-limiting enzyme in the synthesis of
purine nucleotides is amido-phosphoribosyl
transferase (also known as
phosphoribosylpyrophosphate amido
transferase), which is a major target for
two thiol containing purine anticancer
antimetabolites.
6-Mercaptopurine
6
6-Thioguanine
6

6. Azathioprine
Heterocyclicderivativesof6-mercaptopurine,suchas
azathioprine,weredesignedtoprotectitfrom
catabolicreactions.
Althoughazathioprinehasantitumoractivity,itisnot
significantlybetterthan6-mercaptopurine.Ithasan
importantrole,however,asanimmunosuppressive
agentinorgan transplants.
6-Mercaptopurine

7. Purine anticancer agents are both 6-thio analogues of
the endogenous purine bases guanine and purine, also
known as inosine.
They are prodrugs and must be converted to
ribonucleotides by hypoxanthine guanine
phosphoribosyl transferase (HGPRT) before they can
exert their cytotoxic actions.
Mercaptopurine , acting through a methylated
ribonucleotide metabolite , inhibits the target
amidophosphoribosyl transferase enzyme, leading to
the true antimetabolic effect of lowered AMP and
GMP biosynthesis.

8. Mechanism

9. Thiopurines are
methyl transferase (TPMT) with S-adenosylmethionine (SAM) serving as cofactor.
The methylated thiopurine bases cannot
react with HGPRT and, therefore,
form the active false ribonucleotides. The
active false ribonucleotide 6-thioinosinic
acid also is subject to extensive TPMT-
catalyzed methylation.
The S-methyl-6-thioinosinic acid metabolite
is a potent inhibitor of the
amidophosphoribosyl transferase enzyme
and contributes to the cytotoxic action of the
parent drug . In contrast , little or no 6 -
methylthioguanylic acid is produced inside
the cell.
by S-methylation via the polymorphic enzyme thiopurine

10. Mercaptopurine is used in the treatment of acute lymphatic and myelogenous
leukemias.
Theraupetic Uses:
Thiogunanine is administered orally in the treatment of nonlymphocytic
leukemias.
A second mechanism of antineoplastic activity for mercaptopurine (and the
predominantmechanism for thioguanine) involves the incorporation of di- and
triphosphate deoxy- andribonucleotides generated within the tumor cell into
DNA and RNA, respectively. Thisillicit substitution further inhibits elongation of
the strands and promotes apoptosis.

12. dTMP biosynthesis
dTMP is produced via C5-methylation of deoxyuridine monophosphate (dUMP).
The rate-limiting enzyme of the dTMP synthetic pathway is the sulfhydryl-
containing thymidylate synthase, with 5,10-methylenetetrahydrofolate (5,10-
methylene-THF) serving as the methyl-donating cofactor.
All dTMP synthesis inhibitors will inhibit thymidylate synthase either directly or
indirectly, and this will result in a “ thymineless death” in actively dividing cells.
Without dTMP and its deoxythmidine triphosphate metabolite, DNA will
fragment, and the cell will die.
The synthase enzyme is very large and contains a deep pocket for the binding of
both substrate and cofactor.
Thymidylate (dTMP) biosynthesis plays an essential and
exclusive function in DNA synthesis and proper cell division, and
therefore has been an attractive therapeutic target

13. Thymidylate synthase pathway
Abbreviations:
DHFR: dihydrofolate reductase; NADH and NAD+: nicotinamide adenine dinucleotide
(reduced and oxidized forms, respectively); and THF: tetrahydrofolate
https://www.researchgate.net/publication/332688515_An_Additional_Complementary_Mechanism_of
_Action_for_Folic_Acid_in_the_Treatment_of_Megaloblastic_Anemia/figures?lo=1

14. Proton abstracted by cofactor N10.
Ternary Complex
(Enzyme-Substrate-cofactor)
1
2
34
5
6

15. Fluorouracil
To bind to thymidylate synthase, this fluorinated pyrimidine prodrug must be converted to its
deoxyribonucleotide form. The active form of fluorouracil differs from the endogenous substrate
only by the presence of the 5-fluoro group, which holdsthekeytothecell-killingactionofthis
drug.
The C6 position of the false substrate is significantly more
electrophilic than normal because of the strong
electronwithdrawing effect of the C5 fluorine.
This greatly increases the rate of attack by Cys 195 ,
resultinginaveryfastformationofafluorinatedternary
complex.
The small size of the fluorine atom assures no steric
hindrance to the formation of this false complex.

16. The next step in the pathway required
the abstraction of the C5-H (as proton)
by N10 of the cofactor, but this is no
longer possible . Not only is the C5 -
fluorine bond stable to cleavage, the
fluorine atom and N10 would repel one
another because they are both electron
rich.
The false ternary complex cannot break
down, no product is formed, no cofactor
is released, and most importantly, the
rate - limiting enzyme ( thymidylate
synthase) is not regenerated. Because
dTMP can no longer be synthesized, the
cell will die.

18. Fluorouracil is administered IV in the palliative treatment of
. Patients are treated for four consecutive
days, followed by treatment on odd-numbered days up to a maximum of 12
days.

19. Floxuridine
This deoxyribonucleoside prodrug is
bioconverted via 2′-deoxyuridine kinase–
mediated phosphorylationtothesameactive5-
fluoro-dUMPstructuregeneratedinthe
multistepbiotransformationoffluorouracil.
Itisgivenbyintra-arterialinfusionforthe
palliativetreatmentofGIadenocarcinomathat
hasmetastasizedtotheliverandthatcannotbe
managedsurgically.
5-fluorouracil

21. Methotrexate also is effective in inhibiting
glycine amide ribonucleotide ( G A R )
transformylase , a key enzyme in the
synthesis of purine nucleotides.
NOTE:Take note of the structural differencesbetween
methotrexate and DHF, becausethese differences will be
important to anunderstanding of the chemical mechanismof
this anticancer agent .
Pteridine
PABA
Glutamic Acid
Methotrexate
It is a folic acid antagonist structurally designed to competesuccessfully
with 7,8-DHF for the DHFR enzyme. The direct inhibition of DHFRcauses
cellular levels of 7,8-DHF to build up, which in turn results in feedback(indirect
) inhibition of thymidylate synthase.

22. Methotrexate is the classic antimetabolite of folic acid
structurally derived by N-methylation of the para-
aminobenzoic acid residue (PABA) and replacement of
apteridine hydroxyl by the bioisosteric amino group.
The conversion of =O to -NH2 increases the basicity
of N-3 and yields greaterenzyme affinity.
This drug competitively inhibits the binding of the
substrate folic acid to theenzyme DHFR, resulting
in reductions in the synthesis of nucleic acid bases,
perhaps most importantly, the conversion of
uridylate to thymidylate as catalyzedby
thymidylate synthetase.
In addition, purine synthesis is inhibited because the N-10-formyl tetrahydrofolicacid is a
formyl donor involved in purine synthesis. THFs are cofactors in thenormal biosynthesis of
purines.

23. It has been proposed that the N5 position ofDHF is
protonated by a Glu30 of DHFR and, incationic
form, binds to DHFR Asp27 through anelectrostatic
bond. N5 is the strongest base inthe DHF structure,
in part because of attenuatingthe impact of the C4
carbonyl on electrondensity around N1.
Additional affinity - enhancing interactionsbetween
enzyme and substrate also have beenidentified, and
once bound, the substrate 5,6-double bond is
positioned close to the NADPHcofactor so that the
transfer of hydride canproceed.

24. In contrast, the C4 amino substituent of methotrexateenriches
electron density at N1 through π-electron donation,increasing its
basic character between 10- and 1,000-foldandpromoting
protonationbyGlu30attheexpenseofN5.
Because N1 and N5 are across the pteridine ring from one another ,
the interaction of N1 with the DHFR Asp27 will
effectively stand the false substrate “on its head” relative tothe
orientation of 7,8-DHF
.
With the 5,6-double bond of methotrexate 180° away fromthe
bound NADPH cofactor and stabilized by the fullyaromatic
pteridine ring, the possibility for reduction iseliminated. The
DHFR enzyme will be pseudoirreversiblybound to a molecule it
cannot reduce, which ties up theDHFR enzyme and prevents the
conversion of DHF toTHF.
In turn, this halts the synthesis of the 5,10-methylene-THF
cofactor required for dTMP biosynthesis and causes feedback
inhibition of the thymidylate synthase enzyme.The cell will die a
“ thymineless death. ”

25. Methotrexate can be given orally in the treatment of
The sodium salt form also is marketed for IV, intramuscular, intra-arterial, or
intrathecal injection.

26. hydroxymetabolite (which has a three- to fivefold lower water solubility) can
precipitate in the renal tubule, causing damaging crystalluria. Methotrexate-
induced lung disease is a particularly critical problem, because it can arise at any
time and at any dose, and it can even be fatal .
Methotrexate use also can precipitate severe GI side effects, including ulcerative
stomatitis and hemorrhagic enteritis, leading to intestinal perforation. Potentially
fatal skin reactions are a risk as well .
As a Category X teratogen, this drug should not be given to women who are
pregnant or planning to become pregnant.
can occur with high doses if “ third space” fluids allow drug
to accumulate in ascites and pleural ef fusions and/or when renal excretion is
impaired by kidney disease. When used in high doses, methotrexate and its 7-

27. If severe methotrexate toxicity occurs, reduced folate replacement therapy with
5-formyltetrahydrofolate (leucovorin) must be initiated as soon as possible.
Leucovorin generates the folate cofactors needed by DHFR and GAR
transformylase to ensure the continued synthesis of pyrimidine and purine
nucleotides in healthy cells. “Leucovorin rescue” therapy often is given as
prophylaxis after high-dose methotrexate.

28. DNA Polymerase/DNA Chain Elongation
Inhibitors

29. Fivehalogenatedand/orribose-modifiedDNAnucleosideanaloguesaremarketedforthetreatment
ofawidevarietyofhematologiccancersandsolidtumors.
Theseagentshavecomplexandmultifacetedmechanisms.AllincludeinhibitionofDNApolymerase
and/orDNAchainelongationamongtheiractions,however,andallmustbeconvertedto
triphosphatenucleotidesbeforeactivityisrealized.
Asnucleosides,theyareactivelytakenupintocellsviaaselectivenucleosidetransporterprotein,so
tumorsdeficientinthistransportersystemwillberesistanttotheseanticanceragents.
Onceinsidethecell,specifickinasesconducttheessentialphosphorylationreactions.Inactive
triphosphateform,theycanbemistakenlyincorporatedintothegrowingDNAchain,thusarresting
furtherelongation,and/orinhibitenzymesessentialforDNAsynthesis.
AlldrugsinthisgroupareadministeredIV,areexcretedviathekidneys,andinduce
myelosuppressionastheirmajoruse-limitingsideeffect.

30. Cytarabine
Thisiscytidine-basedanticanceragents
undergoinitialphosphorylationby
deoxycytidinekinaseto the
monophosphatewithsubsequent
phosphorylationscatalyzedby
pyrimidinemonophosphate and
diphosphate kinases.
Cytaribine, an arabinoside, is catabolized
by cytidine and deoxycytidylate
(deoxycytidine monophosphate)
deaminases to inactive uracil analogues.

31. REFERENCES:
1.Foye’s Principles of Medicinal Chemistry, Thomas L. Lemke, David A Williams, Lippincott
Williams & Wilkins.
2.Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry, John M.
Beale, John H. Block, Lippincott Williams & Wilkins.